We are live on ! Find out more
CVKD icon

Cadrenal Therapeutics
CVKD

6 hedge funds and large institutions have $408K invested in Cadrenal Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.28% less ownership

Funds ownership: 0.57% → 0.28% (-0.28%)

33% less funds holding

Funds holding: 9 → 6 (-3)

46% less capital invested

Capital invested by funds: $752K → $408K (-$344K)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
6
Holders Change
-3
Holders Change %
-33.33%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$41.8K
2
TRCT
Tower Research Capital (TRC)
New York
+$8
3
Wells Fargo
Wells Fargo
California
+$8

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$300K
2
Citadel Advisors
Citadel Advisors
Florida
-$19.8K
3
VF
Virtu Financial
New York
-$17K
4
TSS
Two Sigma Securities
New York
-$7.37K
5
UBS Group
UBS Group
Switzerland
-$92

CVKD Hedge Fund Activity: Q4 2023 in Review

6 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Cadrenal Therapeutics (CVKD) for Q4 2023, worth a combined $408K — down 46% from $752K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CVKD and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $41.8K. The largest seller was Armistice Capital, cutting an estimated $300K.

  • 6 institutional investors held Cadrenal Therapeutics (CVKD) as of Q4 2023, down from 9 in Q3 2023.
  • Funds reported $408K of Cadrenal Therapeutics stock for Q4 2023, down 46% quarter-over-quarter.
  • 1 fund opened new Cadrenal Therapeutics positions in Q4 2023 and 4 closed out, a net change of -3 holders.
  • The largest Cadrenal Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $41.8K added.
  • The largest Cadrenal Therapeutics seller in Q4 2023 was Armistice Capital, an estimated $300K sold.

Based on aggregated 13F filings for Q4 2023.